Perceptive Advisors LLC Avadel Pharmaceuticals PLC Transaction History

Perceptive Advisors LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$6.41 - $9.95 $3.78 Million - $5.87 Million	590,000 New	590,000 $5.4 Million
Q3 2020 Nov 16, 2020	SELL	$5.02 - $8.98 $43,578 - $77,955	-8,681 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$3.34 - $7.7 $28,994 - $66,843	8,681 New	8,681 $66,000
Q2 2018 Aug 14, 2018	SELL	$5.89 - $7.78 $7.63 Million - $10.1 Million	-1,295,841 Closed	0 $0
Q1 2018 May 15, 2018	SELL	$6.76 - $11.7 $7.41 Million - $12.8 Million	-1,096,000 Reduced 45.82%	1,295,841 $9.45 Million
Q4 2017 Feb 14, 2018	BUY	$8.03 - $11.25 $6.77 Million - $9.48 Million	842,836 Added 54.41%	2,391,841 $19.6 Million
Q3 2017 Nov 14, 2017	BUY	$8.35 - $10.5 $12.9 Million - $16.3 Million	1,549,005	1,549,005 $16.3 Million

1.07M

Ticker AVDL
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 60,581,300
Market Cap $661M
Description
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and...

Get notified when there are updates to the investment portfolio of Perceptive Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Perceptive Advisors LLC with notifications on news.